In a cohort of 1.055 MF patients treated with ruxolitinib, 135 with CALR mutations more frequently developed anemia and increased blast percentages [82], likely reflecting later treatment initiation, higher disease burden, and longer intervals from diagnosis, which may diminish the favorable prognostic impact of CALR mutations. This evidence concerns the gene CALR and anemia (phenotype).